iiinova — where your digital self keeps evolving

Stravitz-Sanyal Institute for Liver Disease and Metabolic Health @vculiver.bsky.social · 30/04/2025

🚨NEW IN #NEJM🚨ESSENCE #VCU-led researchers report weekly injections of #semaglutide resolved steatohepatitis without worsening of fibrosis in 63% of #MASH patients getting weekly semaglutide injections, across 37 countries. #liver www.nejm.org/doi/full/10....

NEJM ESSENCE trial Phase 3 results announced. Semaglutide can resolve MASH. Male doctor speaking with overweight female patient in an exam room.

020

Reposted by Stravitz-Sanyal Institute for Liver Disease and Metabolic Health

Vinay Jahagirdar @vinayjaha.bsky.social · 26/04/2025

Screening for MASLD by at 29th Annual Virginia Liver Symposium by @juanpabloarab.bsky.social @vculiver.bsky.social 🌎 prevalence of MASLD 30% ⬆️ risk progression with DM, HTN, obesity, menopause Screen for 🍷 ♻️ Putative connection between MASLD, CVD, CKD

001

Reposted by Stravitz-Sanyal Institute for Liver Disease and Metabolic Health

Vinay Jahagirdar @vinayjaha.bsky.social · 02/03/2025

Team VCU at AASLD MASLD/MetALD/ALD Emerging Topic Conference 2025, Las Vegas @juanpabloarab.bsky.social @saulkarpen.bsky.social @vculiver.bsky.social

052

Reposted by Stravitz-Sanyal Institute for Liver Disease and Metabolic Health

Jasmohan Bajaj @jasmohanbajaj.bsky.social · 02/03/2025

Thanks #CDDW #CLM Chris Rose & Premsyl Bercik for the invite to speak in a beautiful but freezing Quebec city on #HE #microbes & #gutbrainaxis. Excellent joint session with #microbiology & #gi expertise. 🇨🇦 warmth shone thru despite the polar vortex!! @vculiver.bsky.social

282

Reposted by Stravitz-Sanyal Institute for Liver Disease and Metabolic Health

Jasmohan Bajaj @jasmohanbajaj.bsky.social · 05/02/2025

🙏 @paulsaxmd.bsky.social for the invitation to write this from a #liversky and #IDsky perspective @cidjournal.bsky.social Totally agree the approach needs to shift! @vculiver.bsky.social @idsainfo.bsky.social @easlnews.bsky.social @varesearch.bsky.social

1144

Reposted by Stravitz-Sanyal Institute for Liver Disease and Metabolic Health

Jasmohan Bajaj @jasmohanbajaj.bsky.social · 03/02/2025

🙏 for highlighting our commentary @cidjournal.bsky.social Need to re-evaluate these practices due to ⬆️ - #amr burden - C difficile & #antibiotic adverse events - costs #liversky #gisky @varesearch.bsky.social @idsainfo.bsky.social @amcollegegastro.bsky.social @easlnews.bsky.social

064

Reposted by Stravitz-Sanyal Institute for Liver Disease and Metabolic Health

Jasmohan Bajaj @jasmohanbajaj.bsky.social · 13/01/2025

Check out @nytimes.com interview of experts re: #wellness my tip? Coffee for the win!! Liver brain and microbes all benefit from this Check it out below www.nytimes.com/interactive/... @vculiver.bsky.social @amcollegegastro.bsky.social @ebtapper.bsky.social @easlnews.bsky.social

0166

Reposted by Stravitz-Sanyal Institute for Liver Disease and Metabolic Health

RussCazier 🇺🇸 🇫🇷 🇺🇦 🏳️‍🌈 🇨🇭 ✝️ ❤️is❤️ 🤟🏻is🤟🏻 @russcazier.bsky.social · 14/12/2024

Gastroenterology>General Hepatology FDA Issues Safety Alert on Liver Disease Drug. — Obeticholic acid (Ocaliva) may cause serious liver damage even in PBC patients without cirrhosis. by Ian Ingram, Managing Editor, MedPage Today www.medpagetoday.com/gastroentero...

medpagetoday.com

FDA Issues Safety Alert on Liver Disease Drug

Obeticholic acid (Ocaliva) may cause serious liver damage even in PBC patients without cirrhosis

041

Stravitz-Sanyal Institute for Liver Disease and Metabolic Health @vculiver.bsky.social · 16/12/2024

Taking a first step on Bsky ... here's our team and colleagues at #VCU's Division of GI, Hep and Nutrition. #liversky #gastrosky

Attendees at the year-end party for the VCU Division of GI, Hep, & Nutrition and the Stravitz-Sanyal Institute for Liver Disease and Metabolic Health.

0100